Phase II evaluation of RFT5-dgA [monoclonal antibody ricin chain A conjugate] immunotoxin in patients with metastatic melanoma.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Monoclonal antibody ricin chain A conjugate (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Jul 2012 Actual end date (1 Nov 2008) added as reported by ClincialTrials.gov.
- 11 Jul 2012 Actual end date (1 Nov 2008) added as reported by ClincialTrials.gov.
- 01 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.